In exchange for the exclusive license, Allecra will receive an upfront payment and development and sales milestones for cefepime/enmetazobactam, as well as double-digit tiered royalties.
In addition, the two companies have signed a supply agreement under which Allecra will supply the cefepime/enmetazobactam finished product in the agreed upon territories.
No further financial details have been disclosed.
Cefepime/enmetazobactam is a combination of enmetazobactam, a extended-spectrum β- lactamase inhibitor, combined with the 4th generation cephalosporin cefepime.
Due to their efficacy and safety, β-Lactams are the most widely used class of antibiotics, referred to commonly as penicillins and related β-lactam classes of cephalosporins, and cephamycins, among other names.
Due to the extensive use, a growing number of pathogens have become resistant to a wide range of β-lactam antibiotics, posing a growing risk in both developed and developing countries.
In the US alone, Extended-Spectrum β-lactam Resistant Pathogens (ESBLs) have increased >50% over a six-year period.
The consummation of the licensing transaction is subject to regulatory approval and other customary conditions precedent.
Cefepime/enmetazobactam has been investigated in patients with complicated urinary tract infections (cUTIs) compared to current standard of care in a randomized, controlled, double-blind, global Phase 3 trial.
Based on the positive data readout, Allecra expects to submit for marketing approval in the US and EU.
Cefepime/enmetazobactam has been granted Qualified Infectious Disease Product and Fast Track designation by the US Food and Drug Administration, which will provide five years additional market exclusivity and priority FDA review.
The European Medicines Agency has indicated that, due to the combination of enmetazobactam with the already-approved cefepime and in light of results obtained in an epithelial lining fluid penetration study with cefepime/enmetazobactam, Allecra Therapeutics is allowed to seek approval of cefepime/enmetazobactam for use in pneumonia, including hospital-acquired/ventilator-associated pneumonia (HAP/VAP), without conducting a Phase 3 study in this indication.
Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company developing novel therapies to combat antibiotic resistance by overcoming emergent resistance mechanisms.
Lead product candidate, cefepime/enmetazobactam, has successfully completed a randomized, controlled, double-blind, global Phase 3 trial compared to standard of care in patients with complicated urinary tract infections (cUTIs), and the company is preparing submissions for marketing approval in the US and EU based on these results.
The company has significant patent protection covering proprietary enmetazobactam in major territories.
Allecra's investors include Forbion, Andera Partners, Delos Capital, Xeraya Capital, EMBL Ventures, and BioMedPartners. Allecra's wholly owned French subsidiary is a beneficiary of financial support from Bpifrance and the Région Alsace.
Advanz Pharma is a specialty pharmaceutical company with a strategic focus on hospital medicines in Europe.
With an agile and experienced team, including direct sales, marketing and medical capability across many of Europe's major markets, the company supplies, innovates and enhances the critical medicines patients depend on, ensuring continued patient access and improving health outcomes.
With its European network and its expertise in the anti-infectives and endocrinology therapy areas, Advanz Pharma is an attractive partner when commercializing hospital medicines in Europe.
Advanz Pharma has an operational headquarters in London, an operations centre of excellence in Mumbai, commercial affiliates in North America, Europe, and Australia, and an established global network of commercial partners throughout the rest of the world.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial